Published in Endocr Rev on August 01, 2002
Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ (2006) 5.05
Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int (2008) 2.72
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Bone quality: where do we go from here? Osteoporos Int (2003) 1.64
Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell (2010) 1.60
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int (2006) 1.55
Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int (2006) 1.52
Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int (2007) 1.51
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab (2005) 1.34
Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can (2006) 1.33
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab (2012) 1.18
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol (2007) 1.12
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int (2005) 1.09
Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther (2009) 1.06
Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr (2009) 1.01
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int (2004) 1.00
Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag (2011) 1.00
Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. J Bone Miner Metab (2008) 1.00
The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260]. BMC Public Health (2006) 0.98
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int (2005) 0.95
The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy. Arch Med Sci (2013) 0.94
Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases. Osteoporos Int (2013) 0.93
Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2010) 0.93
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging (2006) 0.93
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res (2008) 0.92
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab (2006) 0.90
Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci (2010) 0.90
The role of bisphosphonates in diseases of childhood. Eur J Pediatr (2003) 0.89
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int (2005) 0.88
Undertreatment of osteoporosis in persons with dementia? A population-based study. Osteoporos Int (2011) 0.88
Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int (2010) 0.87
A sample of Canadian orthopedic surgeons expressed willingness to participate in osteoporosis management for fragility fracture patients. Can J Surg (2008) 0.87
Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface. Osteoporos Int (2008) 0.87
Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect (2007) 0.87
Assessing multiple medication use with probabilities of benefits and harms. J Aging Health (2008) 0.86
Transiliac bone biopsy in osteoporosis: frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years. Clin Rheumatol (2005) 0.86
Bone density testing: an under-utilised and under-researched health education tool for osteoporosis prevention? Nutrients (2010) 0.85
Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry. Clin Orthop Relat Res (2015) 0.85
Loss of life years after a hip fracture. Acta Orthop (2009) 0.85
Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents. J Bone Miner Res (2011) 0.84
Atypical femur fractures: a review of the evidence and its implication to clinical practice. Ther Adv Musculoskelet Dis (2011) 0.83
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.83
Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord (2011) 0.83
Ocular side effects of bisphosphonates: A case report and literature review. Can Fam Physician (2010) 0.81
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis (2007) 0.81
Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int (2007) 0.81
Knowledge on osteoporosis in guardians of hip fracture patients. J Bone Miner Metab (2013) 0.81
Knowledge on osteoporosis of prescriber according to level of medical institute. Yonsei Med J (2014) 0.81
Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database. Clinicoecon Outcomes Res (2013) 0.80
The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. J Bone Miner Metab (2009) 0.80
The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men. J Osteoporos (2011) 0.80
Changes in first hip fracture rates in British Columbia Canada, 1990-2004. Osteoporos Int (2011) 0.80
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study. Osteoporos Int (2009) 0.80
Clinical risk indices, prediction of osteoporosis, and prevention of fractures: diagnostic consequences and costs. Osteoporos Int (2005) 0.80
[Postmenopausal and steroid-induced osteoporosis guideline-orientated prevention and treatment]. Internist (Berl) (2005) 0.79
Stress fracture of the ulna associated with bisphosphonate therapy and use of walking aid. Osteoporos Int (2014) 0.79
Bisphosphonates. Skeletal Radiol (2007) 0.79
The efficacy and safety of a combined alendronate and calcitriol agent (maxmarvil): a postmarketing surveillance study in korean postmenopausal women with osteoporosis. Korean J Fam Med (2012) 0.78
The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging (2007) 0.78
Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcif Tissue Int (2011) 0.78
Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. BMC Musculoskelet Disord (2009) 0.78
Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review. Int J Womens Health (2010) 0.77
Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging (2013) 0.77
Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss. J Bone Miner Metab (2006) 0.77
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers? Osteoporos Int (2009) 0.77
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging (2008) 0.77
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag (2006) 0.77
Impact of clinical preventive services in the ambulatory setting. Proc (Bayl Univ Med Cent) (2008) 0.76
Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol (2013) 0.76
Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med (2015) 0.76
Effects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study. Korean J Intern Med (2011) 0.75
Should all elderly women receive bisphosphonates to prevent osteoporotic fractures? Can J Hosp Pharm (2012) 0.75
Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. J Musculoskelet Neuronal Interact (2017) 0.75
Comparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women. Obstet Gynecol Sci (2013) 0.75
Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis. Int J Clin Exp Med (2015) 0.75
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporos Int (2012) 0.75
Bisphosphonates and skeletal morbidity in patients with metastatic cancer. CMAJ (2003) 0.75
Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (Baltimore) (2017) 0.75
Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study. J Bone Miner Res (2016) 0.75
Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Knowledge on Osteoporosis among Nurses. J Bone Metab (2017) 0.75
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet (2011) 9.31
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) (2012) 9.25
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Withdrawal of mechanical ventilation in anticipation of death in the intensive care unit. N Engl J Med (2003) 7.32
Campaign to revitalise academic medicine kicks off. BMJ (2004) 6.94
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol (2010) 5.78
An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med (2006) 5.29
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med (2008) 5.20
Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med (2003) 5.12
Health research funding agencies' support and promotion of knowledge translation: an international study. Milbank Q (2008) 4.87
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ (2002) 4.70
Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Who cares about academic medicine? BMJ (2004) 4.46
Prospective validation of the San Francisco Syncope Rule to predict patients with serious outcomes. Ann Emerg Med (2006) 4.39
Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol (2006) 4.32
Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA (2004) 4.18
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ (2004) 4.13
Open letter to the leader of academic medicine. BMJ (2007) 4.06
Evaluating the teaching of evidence-based medicine. JAMA (2002) 4.01
Five futures for academic medicine. PLoS Med (2005) 3.95
Clinical experts or methodologists to write clinical guidelines? Lancet (2009) 3.91
Interventions to reduce unintended pregnancies among adolescents: systematic review of randomised controlled trials. BMJ (2002) 3.90
Out-of-hospital pediatric cardiac arrest: an epidemiologic review and assessment of current knowledge. Ann Emerg Med (2005) 3.79
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol (2013) 3.58
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) (2007) 3.51
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 3.41
The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology (2005) 3.33
The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology (2005) 3.33
Patients at the center: in our practice, and in our use of language. ACP J Club (2004) 3.32
Randomized controlled trials of surgical interventions. Ann Surg (2010) 3.30
Naturopathic medicine for the prevention of cardiovascular disease: a randomized clinical trial. CMAJ (2013) 3.25
Tips for learning and teaching evidence-based medicine: introduction to the series. CMAJ (2004) 3.23
Cast versus splint in children with minimally angulated fractures of the distal radius: a randomized controlled trial. CMAJ (2010) 3.15
Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition. Med Care (2002) 3.05
The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med (2008) 3.01
Randomized trial of reamed and unreamed intramedullary nailing of tibial shaft fractures. J Bone Joint Surg Am (2008) 3.01
Applying clinical epidemiological methods to health equity: the equity effectiveness loop. BMJ (2006) 3.00
Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res (2012) 2.85
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med (2011) 2.80
What types of interventions generate inequalities? Evidence from systematic reviews. J Epidemiol Community Health (2012) 2.80
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
Clinician predictions of intensive care unit mortality. Crit Care Med (2004) 2.65
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (2009) 2.61
Cooling for neonatal hypoxic ischemic encephalopathy: do we have the answer? Pediatrics (2007) 2.51
Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst (2003) 2.51
Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol (2003) 2.47
GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol (2013) 2.46
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol (2009) 2.45
Evidence based medicine has come a long way. BMJ (2004) 2.42
STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med (2009) 2.39
PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS Med (2012) 2.31
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol (2008) 2.31
A comparison of the quality of Cochrane reviews and systematic reviews published in paper-based journals. Eval Health Prof (2002) 2.29
Flossing for the management of periodontal diseases and dental caries in adults. Cochrane Database Syst Rev (2011) 2.29
Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med (2010) 2.28
Outcomes of children at 2 years after planned cesarean birth versus planned vaginal birth for breech presentation at term: the International Randomized Term Breech Trial. Am J Obstet Gynecol (2004) 2.26
Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol (2006) 2.23
Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol. CMAJ (2006) 2.20
Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol (2003) 2.20
Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol (2008) 2.18
Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med (2015) 2.16
Family impact of child oral and oro-facial conditions. Community Dent Oral Epidemiol (2002) 2.09
Realist review to understand the efficacy of school feeding programmes. BMJ (2007) 2.08
Canada urgently needs a national network of libraries to access evidence. Healthc Q (2006) 2.07
Celiac disease: evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics (2005) 2.07
Clonidine in patients undergoing noncardiac surgery. N Engl J Med (2014) 2.07
Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Joint Surg Am (2005) 2.05
The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One (2011) 2.02
Avoidable mortality by neighbourhood income in Canada: 25 years after the establishment of universal health insurance. J Epidemiol Community Health (2007) 2.02
Complex interventions and their implications for systematic reviews: a pragmatic approach. J Clin Epidemiol (2013) 1.98
Barriers to participating in an HIV vaccine trial: a systematic review. AIDS (2004) 1.97
Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol (2007) 1.94
The effect of hospital occupancy on emergency department length of stay and patient disposition. Acad Emerg Med (2003) 1.93
A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ (2003) 1.93
Survey of interventions for the prevention and treatment of acute respiratory distress syndrome. Crit Care Med (2004) 1.90
Teaching evidence-based complementary and alternative medicine: 1. A learning structure for clinical decision changes. J Altern Complement Med (2002) 1.90
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87